Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B

Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B

The aim of this review is to outline emerging biomarkers that can serve as diagnostic tools to identify non-cirrhotic chronic hepatitis B (CHB) patients who could safely discontinue nucleos(t)ide analogues (NAs) before HBsAg loss. Regarding possible predictors of post-NAs outcomes, a number of studi...

Full description

Bibliographic Details
Main Authors: Margarita Papatheodoridi, George Papatheodoridis
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Cells
Subjects:
discontinuation
nucleos(t)ide analogues
hepatitis b
hbsag
hbcrag
relapse
retreatment
remission
hbsag loss
Online Access:https://www.mdpi.com/2073-4409/9/2/493

Internet

https://www.mdpi.com/2073-4409/9/2/493

Similar Items